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FASTTRACK
Dominant-Negative CREB Inhibits Heparanase
Functionality and Melanoma Cell Invasion
Rebecca Aucoin, Jane Reiland, Madhuchhanda Roy, and Dario Marchetti*
Department of Comparative Biomedical Sciences, School of Veterinary Medicine,
Louisiana State University-Baton Rouge, Baton Rouge, Louisiana 70803
Abstract Heparanase (HPSE-1) is an endo-b-D-glucuronidase involved in the degradation of cell-surface/
extracellular matrix heparan sulfate (HS) in normal and neoplastic tissues. HPSE-1 represents the first example of
purificationandcloningof amammalianHS-degradative enzyme. ElevatedHPSE-1 levels are known tobe associatedwith
metastatic cancers, directly implicatingHPSE-1 inmetastatic events. The purpose of this studywas to determine the role of
cAMP response element-binding protein (CREB) in modulating HPSE-1-mediated effects on human melanoma cell
invasion. Highly invasive, brain-metastatic melanoma cells (70W) were transfected with the dominant-negative CREB
(KCREB) and subsequently analyzed for changes in their HPSE-1 content, functionality, and cell invasive properties.
KCREB-transfected cells showed a decrease in HPSE-1mRNA expression and activity. This correlated with a significantly
decreased invasion of these cells through MatrigelTM-coated filters. Furthermore, adenoviral vectors containing the full-
length human HPSE-1 cDNA in sense orientation (Ad-S/hep) were constructed to investigate CREB effects on HPSE-1.
Restoration of HPSE-1 expression and functionality following Ad-S/hep infection of KCREB-transfected 70W cells
recoveredmelanoma cell invasiveness. These results demonstrate that KCREB inhibits HPSE-1 and suggest that one of the
roles CREB plays in the acquisition of melanoma cells metastatic phenotype is affecting HPSE-1 activity. J. Cell. Biochem.
93: 215–223, 2004.  2004 Wiley-Liss, Inc.
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Most of molecular events associated with
melanoma growth, neovascularization, and
metastasis are influenced by interactions
between neoplastic cells and components of
their extracellular matrix (ECM) [Herlyn and
Shih, 1994; Kopf et al., 1995]. Heparan sulfate
proteoglycans (HSPG), along with other proteo-
glycans and structural proteins, are key compo-
nents of the cell surface and ECM [Bernfield
et al., 1999; Sanderson, 2001]. The realization
that cell-surface HSPG mediate extracellular
information has raised questions about their
selective degradation at the heparan sulfate
glycosaminoglycan chains (HS) level.
Heparanase (HPSE-1) is an endo-b-D-glucur-
onidase that cleaves HS at specific intrachain
sites, resulting in the formation of fragments
(10–20 sugar units) [Nakajima et al., 1984,
1988; Vlodavsky and Friedmann, 2001] which
are capable of binding potent angiogenic and
paracrine growth factors [Vlodavsky and Fried-
mann, 2001]. Importantly, HPSE-1 is to be
distinguished from other HS-degradative
enzymes, such as heparitinases and hepari-
nases from Flavobacterium heparinum, or
endoglucosaminidases, which are eliminases
that cleave HS into non-biologically active
 2004 Wiley-Liss, Inc.
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di- or tetra-saccharide units [Liu et al., 2002].
Increased levels of HPSE-1 activity are asso-
ciated with several metastatic tumor types
[Marchetti et al., 1996; Vlodavsky and Fried-
mann, 2001], including brain-metastatic mela-
noma [Marchetti et al., 1993, 1996, 2003;
Marchetti and Nicolson, 2001], and HPSE-1
has been also implicated in tumor angiogenesis
[Vlodavsky and Friedmann, 2001]. Because
melanocyte proliferation and differentiation
are positively regulated by agents that increase
cAMP [Gonzalez and Montminy, 1989], we
have focused on the transcription factor cAMP
response element-binding protein (CREB)
which is known to be activated by cAMP.
The 43 kDa CREB protein binds the consen-
sus motif 50-TGACGTCA-30 and activates tran-
scription. It was initially isolated from rat brain
tissue [Gonzalez and Montminy, 1989] and
found to be ubiquitously expressed belonging
to the leucine zipper class of proteins [Borrelli
et al., 1992]. The CREB protein is an important
transcription factor which is activated bymulti-
ple signal transduction pathways in response to
hormones, growth factors, cytokines, and stress
[Gonzalez andMontminy, 1989]. CREB is also a
mediator of tumor growth and metastasis of
human melanoma [Yang et al., 1996; Xie et al.,
1997; Jean et al., 1998; Jean and Bar-Eli, 2000].
CREB overexpression is found in melanoma
progression fromradial growthphase to vertical
phase [Nyormoi and Bar-Eli, 2003]. Inhibiting
CREB activity with a dominant negative CREB
reduces melanoma metastatic potential [Xie
et al., 1997]. CREB also regulates the expres-
sion of type IV collagenase (MMP-2) and the
cell-surface adhesion molecule MUC18, both of
which can contribute to the invasive phenotype
of melanoma cells [Jean and Bar-Eli, 2000].
Additionally, CREB acts as a survival factor for
melanoma by reducing susceptibility to apopto-
sis [Jean et al., 1998].
To study the contribution of CREB toHPSE-1
expression and activity as related to human
melanoma metastasis, we have used a domi-
nant-negative cDNA construct of CREB,
KCREB that has been mutated in the DNA-
binding domain [Walton et al., 1992; Xie et al.,
1997]. When overexpressed, this protein sup-
presses transcription of factors capable of
associating with CREB [Wada et al., 1991;
Abdel-Hafiz et al., 1993].
In the present study, we have demonstrated:
(1) a KCREB-mediated inhibition of cell inva-
sion by highly aggressive and brain-metastatic
human melanoma cells (70W); (2) a down-
regulation of HPSE-1 mRNA and activity (but
not protein) in KCREB-transfected 70W cells;
and (3) a restoration of cell invasiveness when
KCREB-transfected 70W cells were infected
with an adenoviral vector expressing human
HPSE-1 (Ad-S/hep). These results demonstrate
for the first time that CREB regulates mela-





F-12 nutrientmedium and trypsin–EDTAwere
purchased from Gibco (Grand Island, New
York, NY), and fetal bovine serum (FBS) from
Hyclone Laboratories (Logan, UT). Transwell
cell culture chambers were purchased from
Corning Incorporated Life Sciences (Acton,
MA), while MatrigelTM was obtained from BD
Biosciences Discovery Labware (Bedford, MA).
Lipofectin was purchased from Invitrogen, Inc.
(Carlsbad, CA). Polyclonal antibodies to human
HPSE-1 were kindly provided by Dr. Laurie A.
Dempsey (Mayo Clinic, Rochester, MN). All
other chemicals used were reagent-grade or
better.
Tissue Culture
Human brain-metastatic melanoma 70W
cells were maintained as monolayer cultures
in a 1:1 (v/v) mixture of DMEM/F-12 supple-
mented with 10% (v/v) FBS [Marchetti et al.,
1996, 2003; Reiland et al., 2004]. Human 70W
cells were chosen as because they are highly
invasive and produceHPSE-1 at elevated levels
versus parental MeWo [Marchetti et al., 1993,
1996]. Cells were maintained at 378C in a
humidified 5% CO2, 95% air (v/v) atmosphere
andpassagedusing trypsin-EDTAbefore reach-
ing confluency. The transformed embryonic
kidney cell line 293 was grown in DMEM/F-12,
supplemented with 10% FBS, penicillin (100 U/
ml), and streptomycin (100 mg/ml). The 293 cells
were used for the production of adenoviral
vectors [Uno et al., 2001].
Dominant Negative CREB (KCREB)
The production of the dominant-negative
KCREB (pRSV-KCREB) plasmid and subse-
quent luciferase assays were performed as
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previously described [Wada et al., 1991; Walton
et al., 1992; Yang et al., 1996].
Recombinant Adenovirus
Containing Human HPSE-1
An adenoviral expression vector kit (Takara
Biomedicals, Inc., Tokyo, Japan) was used to
generate recombinant adenovirus for the
expression of human HPSE-1 [Uno et al.,
2001]. Replication-deficient E1- and E3-deleted
recombinant adenovirus serotype 5 (Ad5) was
used as the viral backbone. Plasmid DNA
containing the clonedHPSE-1and the synthetic
oligonucleotides Hep-50 (complementary to the
50 end of the gene) and Hep-30 (complementary
to the30 endof thegene)wereused to createPCR
products encompassing the HPSE-1 sequence
(1,632 bp). PCR products were treated with T4
DNA polymerase to generate uniformed blunt
ends required for the elongation reaction into a
pAxCAwt cosmid provided by the Takara kit.
After cloning HPSE-1 into the cosmid vector,
availability of recombinant cosmids containing
the target gene in sense (50–30 orientationunder
theCAGpromoter of the vector) orientationwas
confirmedby restriction analysis. CosmidDNAs
were produced in large quantities and after
gradient purification were used for cotransfec-
tion with the adenovirus genomic DNA-term-
inal protein complex (DNA-TPCprovided by the
kit) into the 293 cells. Following the protocol,
recombinant adenoviruses expressing human
HPSE-1 in sense orientation (Ad-S/hep) were
generated. Integrity of recombinantviruseswas
confirmed using PCR and restriction analysis.
The E1- and E3-deleted replication deficient
adenovirus pAd5-Blue was used as control
vector. Viral titer was quantified by determina-
tion of the 50% infectivity on tissue culture
293 cells (TCID 50).
KCREB Transfection and Adenoviral Infection
70Wcellswere plated in 6-well (106 cells/well)
tissue culture dishes (Corning, Inc., New York).
Twenty-four hours later, they were washed
twice in serum-free DMEM/F-12. Cells were
then transfected with KCREB or mock trans-
fected using lipofectin (10 mg/ml) following a
commercially available protocol (Invitrogen,
Inc.). After 24 hr, cells were washed twice with
phosphate-buffered saline (PBS) containing
2 mM EDTA, and then infected with the
adenovirus vectors (Ad-S/hep or pAd5-Blue)
diluted in serum-free DMEM/F12. Cells were
infected with vectors at a multiplicity of infec-
tion (MOI) of 50. Plates were incubated for 1 h,
rocking every 10 min. Infection was stopped by
adding DMEM/F12 containing 10% FBS, peni-
cillin (100 U/ml), and streptomycin (100 mg/ml).
Cells were then incubated for additional
24 h at 378C in a humidified 5% CO2, 95%
air (v/v) atmosphere before experiments were
performed.
Isolation of RNA, HPSE-1 Primers, and RT-PCR
Total RNA was isolated from cells using
RNeasy kit (Qiagen, Inc., Valencia, CA). Re-
verse transcription was performed using oligo-
dT primers as per manufacturer’s instructions
(Promega, Madison, WI) and PCR was per-
formed for 35 cycles of denaturation at 948C for
30 s, annealing at 568C for 30 s, and at 728C for
1min using a thermal cycler (ABI 9600, Applied
Biosystems, Foster City, CA). The following
specific primers were used: HPSE-1 sense
(HPSE-S: 50-GTT GCT CCT GGA CTA CTG
CTC TT-30), and antisense (HPSE-AS: 50-AGC
CAC ATA AAG CCA GCT GC-30); control
glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), sense (50-AGC CAC ATC GCT CAG
AAC AC-30), and antisense (50-GAG GCA TTG
CTG ATG ATC TTG-30). PCR products were
subsequently resolved ona1.5%agarose gel and
visualized by ethidiumbromide stainingusing a
Versadoc imaging system (Bio-Rad Labora-
tories, Hercules, CA).
Western Blotting Analysis
Cells to be analyzed for CREB protein ex-
pression were plated in 6-well dishes and
incubated at 378C for 24 h. Cells were then
transfected with KCREB plasmid. Forty-eight
hours later, they were scraped off the dish in
cold (48C) PBS and nuclear extract was sepa-
rated fromtotal cell extract [Xie et al., 1997].For
studies involving HPSE-1, cells were subse-
quently infected with Ad-S/hep (or pAd5-Blue
control) and incubated for an additional 24 h
after transfectionwithKCREB. Theywere then
released using trypsin, centrifuged at 300 rpm
for 5 min, and resuspended in lysis buffer [tris-
buffered saline, TBS (pH7.4) containingTriton-
X 100 (0.5%), leupeptin (10 mg/ml), pepstatin
(10 mg/ml), and phenyl methyl sulfonyl fluoride
(PMSF) (0.2 mM)]. Cells were vortexed and
lysed on ice for 10 min. They were then centri-
fuged for 10 min at 13,000 rpm at 48C, and the
supernatant was collected. For KCREB and
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HPSE-1 detection, protein concentration was
determined using a bicinchoninic acid (BCA)
assay (Pierce, Rockford, IL). BecauseHPSE-1 is
a low-abundance protein, 40–60 mg of total cell-
lysate had to be electrophoresed in order to
detect adequate HPSE-1 levels. Protein sam-
ples (40–60 mg) were heated to 1008C for 5 min
with Laemmli sample buffer [Laemmli, 1970]
and separated on a 10%Criterion gel (Tris-HCl,
Bio-Rad Laboratories). The gel was transferred
to a polyvinylidene difluoride (PDVF) mem-
brane (Pierce Endogen, Inc., Rockford, IL) and
incubated for 1 h in a blocking reagent [3% (w/v)
non-fat dry milk, 0.5% (w/v) bovine serum
albumin (BSA), 0.3% (v/v) Tween-20 on PBS,
pH 7.5]. CREBwas labeled using an anti-CREB
antibody which recognizes both CREB and
KCREB (1:500 dilution) (Santa Cruz Biotech-
nology, Inc., SantaCruz, CA)whileHPSE-1was
labeled using anti-HPSE-1 polyclonal antibody
(PAb) (1:5,000). Membranes were incubated
with either antibody in 3% (w/v) non-fat dry
milk and 0.5% (w/v) BSA for 18 h. They were
then washed with 0.5% IGE-PAL (CA-630,
Sigma Chemical Company, St. Louis, MO) in
Tris-buffer (20 mM Tris, 150 mMNaCl, pH 7.4)
for 1 h, changing the solution six to eight times.
PDVF membranes were then incubated with
secondary antibodies in 3% (w/v) non-fat dry
milk and 0.5% (w/v) BSA for 30 min. Goat anti-
mouse-horse radish peroxidase (HRP) antibody
was used for CREB (1:10,000 dilution; Bio-Rad
Technologies, Inc., Hercules, CA), and bovine
anti-rabbit-HRP antibody was used for HPSE-1
detection (1:5,000 dilution; Santa Cruz Bio-
technology, Hercules, CA). Membranes were
washed and developed using the Super-signal
west femto maximum sensitivity substrate
(Pierce Endogen, Inc.). Labeling was detected
using the Versadoc imaging system (Bio-Rad).
Chemoinvasion Assays
Cell invasion (72 h) was assayed using
Transwell cell culture chambers (8 mm pore
size, 6.5 mm diameter) coated with artificial
basement membrane or MatrigelTM (diluted
1:30 with cold DMEM/F-12, 100 ml final coating
volume) as previously described [Reiland et al.,
2004].
HPSE-1 Activity Assays
A commercialHSdegrading enzyme assay kit
(Takara Mirus Biomedical, Inc., Madison, WI)
was used to determine HPSE-1 activity in the
presence or absence of KCREB. Cells equiva-
lents (2.5 106/well) were incubated with a
biotinylated-HS (b-HS) and detected by an
enzyme-linked immunosorbent assay (ELISA)-
type assay according to the manufacturer’s
instructions. Activity was determined by com-
parison to known HPSE-1 activity values
obtained from standards supplied by the kit
[Reiland et al., 2004].
RESULTS
KCREB Inhibits 70W Cell Invasion Through
Matrigel-Coated Filters
Brain-metastatic 70W cells were compared
before and after transfection with KCREB
mutant gene to assess the role of CREB in cell
penetration through the basement membrane,
an important barrier which must be breached
for tumor cells to invade andmetastasize [Liotta
et al., 1991; Wada et al., 1991; Bogenrieder and
Herlyn, 2003]. First, CREB expression was
confirmed at the protein level by performing
Western blotting analyses using an antibody
which recognized both CREB and KCREB
(Fig. 1A). Second, we performed chemoinvasion
assays using an artificial basement membrane
(MatrigelTM). Cells (70W) exhibited high cap-
abilities to penetrate through Matrigel-coated
filters [Marchetti et al., 1993, 1996; Fig. 1B].
Conversely, KCREB-transfected 70W cells dis-
played a significantly decreased (4.5-fold;
P< 0.001) ability to invade through these filters
(Fig. 1B). These studies show that expression
of KCREB by melanoma cells decreased their
capacity to penetrate though the basement
membrane.
KCREB-Transfected 70W Cells Show
Decreased HPSE-1 Transcript Expression
The metastatic potential of tumor cells
depends on proper vascularization of the tumor
and its ability to degrade HSPG. Downregula-
tion or deactivation of HPSE-1 may account for
the decrease in invasiveness of KCREB-trans-
fected 70W cells. To examine the significance of
KCREB in affecting human HPSE-1 in brain-
metastatic melanoma, we transfected 70W cells
with a KCREB-containing vector and investi-
gated its effects on HPSE-1 transcript expres-
sion. A specific HPSE-1 transcript (470 bp)
amplification was detected by semiquantitative
RT-PCR which was significantly downregu-
lated in KCREB-transfected cells (Fig. 2).
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Decrease of HPSE-1 Activity
in KCREB-Transfected Cells
Asa subsequent step in our investigations,we
analyzed HPSE-1 activity in KCREB-trans-
fected 70W cells. Cell lysates from these cells
were analyzed for HPSE-1 activity as we have
previously described [Reiland et al., 2004]. A
36% decrease in HPSE-1 activity in KCREB-
transfected 70Wcellswas observed compared to
control 70W (Fig. 3). Furthermore, an inhibition
of HPSE-1 activity in KCREB-transfected 70W
cells correlated with the observed decrease
in HPSE-1 mRNA transcript in KCREB-
transfected 70W cells (Fig. 2).
HPSE-1 Modulation by Ad-S/hep Infection
of KCREB-Transfected 70W Cells
To examine the effects of Ad-S/hep infection
on HPSE-1 mRNA and protein levels in
KCREB-transfected 70W cells, we performed
RT-PCR and Western blotting analyses. Cells
(70W) were transfected with KCREB or mock
controls. Cells, previously KCREB-transfected,
and subsequently infected with Ad-S/hep
showed an increase in HPSE-1 transcript
(Fig. 4A, lanes 2 and 4). HPSE-1 is a hetero-
dimer consisting of a 50 kDa and a 8 kDa
band processed from a pro-enzyme precursor
(65 kDa) by proteolytic cleavage. Presence of
the 8 kDa band is essential for its enzymatic
activity [Fairbanks et al., 1999; McKenzie
et al., 2003]. Consistent with these findings,
we detected a 58 kDa as active heterodimer
produced in our cells (Fig. 4B). We found a 23%
increase inHPSE-1 protein level whenKCREB-
transfected 70Wcellswere infectedwith theAd-
S/hep. However, and of note, HPSE-1 protein
levels remained unchanged among the various
treatments (Fig. 4B).
Fig. 1. Cells (70W) transfected with dominant-negative CREB
(KCREB) mutant show increased cAMP response element-
binding protein (CREB) protein expression by Western blotting
but a decreased invasion. A: Western blotting analysis using an
anti-CREB antibody, which recognizes both CREB and KCREB.
Nuclear extract was taken from cells transfected with KCREB.
Cells transfected with KCREB (lane 2) display an increase in the
43 kDa band, showing successful transfection of the KCREB
plasmid. B: Brain-metastatic 70W cells were transfected with
dominant negative KCREB and placed onto invasion chambers
(8 mm pores) for 72 h at 378C. Cells that invaded through an
artificial basement membrane (MatrigelTM) were stained with
the Diff-Quick staining kit, photographed, and counted (see
‘‘Materials andMethods’’). KCREB-transfected70Wcells (lane2)
show a significant decrease in invasion versus mock control
(lane 1). Bars represent the mean SD of triplicate determina-
tions (*P< 0.001). Student’s t-test was used as statistical method.
Fig. 2. Dominant-negative KCREB inhibits heparanase (HPSE-
1) mRNA expression. RT-PCR analysis for HPSE-1 transcript
expression in 70W cells transfected with KCREB using lipofectin
(lane 2) or incubated with lipofectin alone as control (lane 1).
Fig. 3. KCREB inhibits HPSE-1 activity. HPSE-1 activity assays
in cell lysates of 70W cells transfected with KCREB or mock
control. HPSE-1 activity was determined by comparison with
known standards (see ‘‘Materials and Methods’’).
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Infection of KCREB-Transfected 70W Cells
With Ad-S/hep Restores Invasive Capabilities
To investigate whether HPSE-1 directly
correlated with a loss in CREB functionality,
KREB-transfected 70Wcellswere subsequently
infected with either Ad-S/hep or pAd5-Blue
control. These cells then were then plated onto
Matrigel-coated filters and chemoinvasion as-
says performed. Cells showed decreased inva-
siveness when expressing the KCREB protein,
however, HPSE-1 activity was restored follow-
ing Ad-S/hep as well as cell ability to invade
(Fig. 5).
DISCUSSION
In this report, we demonstrate for the first
time that (1) CREB is involved in HPSE-1-
mediated invasive mechanisms, and (2) domi-
nant negative CREB (KCREB) inhibits HPSE-1
functionality in brain-metastatic melanoma
cells (70W). We showed that expression of
dominant-negative KCREB in 70W cells mark-
edly reduces HPSE-1 mRNA and activity
(Figs. 1 and 4). Our results also demonstrate
that KCREB regulates HPSE-1 transcription
(Fig. 2) but not HPSE-1 protein expression
(Fig. 4B) and furthermore that the infection of
KCREB-transfected 70W cells with Ad-S/hep
restores their invasive capabilities (Fig. 5).
The molecular basis of human malignant
melanoma progression has remained largely
unknown despite the fact that the worldwide
incidence of melanoma is increasing more than
that of any other neoplastic disease [Herlyn and
Shih, 1994; Kopf et al., 1995]. Invasion and
Fig. 4. RT-PCR and Western blotting analysis of KCREB-
transfected 70W infected with Ad-S/hep. A: Cells (70W) were
transfectedwithKCREB (lanes3and4) or incubatedwith lipofectin
alone (lanes 1 and 2). They were then subsequently infected with
Ad-S/hep (lanes2and4)orcontrol pAd5-Blue (lanes1and3).Cells
infected with Ad-S/hep showed an increase in HPSE-1 transcript.
B: Western blotting analysis for HPSE-1. Cells (70W) were
transfected with KCREB and analyzed for HPSE-1 content. Equal
amounts (40–60 mg) of protein were loaded on gels and HPSE-1
protein levels were detected using a rabbit polyclonal antibody
and horse radish peroxidase (HRP)-anti-rabbit immunoglobulin G
(IgG) followed by using the Super-signal west femto maximum
sensitivity substrate (see ‘‘Materials and Methods’’). Bands were
visualized on a Versadoc imaging system. Panel 1: Mock control.
Panel 2: KCREB-transfected 70W cells. Lanes 1 and 4: No
treatment; (lanes 2 and 5) 70W transfectedwith pAd-5Blue; (lanes
3 and 6) 70W transfected with Ad-S/hep.
Fig. 5. Ad-S/hep restores invasive capabilities of 70W cells
transfected with KCREB. Cells (70W) were transfected with
lipofectin (control) or with KCREB using lipofectin. They were
then infected using Ad-S/hep or pAd5-Blue. KCREB-transfected
70W and infected with pAd-S-Blue showed inhibition invasion
throughMatrigel-coated filters. InfectingKCREB transfected cells
withAd-S/hep restored invasion.Bars represent themean SDof
triplicate determinations (*P< 0.001). Student’s t-test was used
as a statistical method.
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metastasis are characteristic features of malig-
nant tumors like melanoma, and are among the
greatest impediments to curing cancer [Liotta
et al., 1991; Bogenrieder and Herlyn, 2003].
Their invasive potential depends, among many
factors, on their ability to degrade HSPG. In-
deed, HPSE-1 activation provides a mechanism
to explain the increased metastatic potential of
human melanoma cells [Marchetti et al., 1993].
The dominant-negative construct KCREB
used in this study displays an altered CREB
DNA-binding activity due to a single base pair
change from arginine to leucine at position 287.
This arginine is conserved within the basic
region of the leucine zipper DNA-binding motif
in more than 30 different members of the AP1/
ATF family of transcription factors [Ellenberger
et al., 1992]. The KCREB protein yields proper
heterodimerization with AP1/CRE-binding fac-
tors, however, due to its poor affinity to DNA,
CREB-associated proteins confer an altered
transcriptional activity. As a result, expression
of the dominant negativeCREBwill quench any
of the known CREB-associated proteins includ-
ing members of the ATF [Wada et al., 1991;
Abdel-Hafiz et al., 1993], AP1 families [Hai and
Curran, 1991], and the 265 kDa CREB-binding
protein (CBP) that links CREB to the basal
transcriptionmachinery through its association
with TFIIB [Kwok et al., 1994]. In the KCREB
clone used in the present study, endogenous
CREB may still interact with CRE target se-
quences, yet, due to the quenching properties of
KCREB, endogenousCREB is likely to associate
with different transcription factors. Such a
change would result in different size complexes
and modified transcriptional activities.
One mechanism of CREB transcriptional
activation is its phosphorylation of Ser-133 by
the catalytic subunit of cAMP-activated protein
kinaseA [Gonzalez andMontminy, 1989].Many
other Ser/Thr kinases can phosphorylate CREB
including proteinkinaseC [Borrelli et al., 1992].
It is interesting to note that regulation ofHPSE-
1 expression and secretion by protein kinase A
and protein kinase C has been recently reported
[Navarro et al., 2004]. Of note, CREB may not
directly regulate HPSE-1 since CRE sites have
not been detected in HPSE-1 promoter [Jiang
et al., 2002].
Down-regulation of HPSE-1 activity might
be one of the mechanisms that account for
the decrease in invasiveness of the KCREB-
transfected cells (Fig. 1B). Recent findings from
other laboratories imply that in addition to
contributing to HSPG degradation, HPSE-1
also mediate adhesion of neoplastic cells to the
ECM [Goldshmidt et al., 2003]. As such, HPSE-
1 may modulate adhesion and facilitate cell
migration and invasion.
Heparanase is regulated at multiple levels
including during transcription, translation
[Shteper et al., 2003; Chen et al., 2004], post-
translational events due to glycosylation or
protein cleavage [Fairbanks et al., 1999;
McKenzie et al., 2003; Simizu et al., 2004], and
sub-cellular localization [Sasaki et al., 2004].
Thesemultiple layers of regulation can result in
HPSE-1 message, protein, or whole cell enzy-
matic activity levels which may not directly
correlate with heparanase-mediated biological
activity. As an example, HPSE-1 is made as a
65 kDa pro-enzyme which needs to be cleaved
for enzymatic activity [Fairbanks et al., 1999;
McKenzie et al., 2003]. Of relevance, increases
in HPSE-1 activity without corresponding
increases in its protein levels have recently
been reported and are consistent with our
results [He et al., 2004]. This may reflect
changes in HPSE-1 localization that can alter
its activity levels in cells. It has been reported
that changes in HPSE-1 localization, i.e., to the
cell surface, can lead to increases in hepara-
nase-mediated function [Sasaki et al., 2004].
CREB is known to regulate a cassette of
genes. Therefore, and as determined in our
experiments, CREB may regulate HPSE-1 at
multiple levels. Thiswasunexpected butmaybe
due to the above-mentioned extensive HPSE-1
regulatory patterns.
In summary, our data demonstrate that the
transcription factor CREB is involved in reg-
ulatingHPSE-1gene transcription, activity and
functionality. Since HPSE-1 is involved in the
progression of malignant melanoma, these
results suggest that CREB and possibly its
associated proteins may play important roles in
the acquisition of the brain-metastatic pheno-
type of human melanoma cells.
The therapeutic modalities to control tumor
growth and metastasis of human melanoma
are very limited. Based on our studies that
CREB serves as HPSE-1 modulator, it is
conceivable to use CRE-based oligonucleo-
tides as a decoy transcription factors to inhibit
HPSE-1 and melanoma metastasis. This possi-
bility is currently being investigated in our
laboratory.
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